tirzepatide surmount-1 percent weight loss 72 weeks Trial In an earlier analysis of

2025 Nov;33(11):2046-2054

At the same time, people with psychiatric disorders are more likely to develop metabolic conditions such as obesity and diabetes

Tirzepatide, a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, follows a structured titration schedule with dose increases typically occurring every four weeks

This classification permits the use of research chemicals exclusively for in vitro testing and laboratory experiments

In the non-PAP group, tirzepatide reduced the apnea-hypopnea index by 25.3 events per hour at 52 weeks, compared with 5.3 events per hour for placebo